Skip to main content

Tussionex Pennkinetic Dosage

Generic name: hydrocodone 10mg in 5mL, chlorpheniramine 8mg in 5mL
Dosage form: suspension, extended release
Drug class: Upper respiratory combinations

Medically reviewed by Last updated on Aug 10, 2022.

Important Dosage and Administration Instructions

Administer TUSSIONEX Pennkinetic by the oral route only. TUSSIONEX Pennkinetic can be taken with or without food. Shake well before using. Do not mix TUSSIONEX Pennkinetic with other liquids or medicines. Mixing may change how TUSSIONEX Pennkinetic works.

Always use an accurate milliliter measuring device when administering TUSSIONEX Pennkinetic to ensure that the dose is measured and administered accurately. A household teaspoon is not an accurate measuring device and could lead to overdosage [see Warnings and Precautions (5.5)]. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. Do not overfill. Rinse the measuring device with water after each use.

Advise patients not to increase the dose or dosing frequency of TUSSIONEX Pennkinetic because serious adverse events such as respiratory depression may occur with overdosage [see Warnings and Precautions (5.2) and Overdosage (10)]. The dosage of TUSSIONEX Pennkinetic should not be increased if cough fails to respond; an unresponsive cough should be reevaluated for possible underlying pathology [see Dosage and Administration (2.3) and Warnings and Precautions (5.4)].

Recommended Dosage

Adults 18 years of age and older: 5 mL every 12 hours as needed, not to exceed 2 doses (10 mL) in 24 hours

Monitoring, Maintenance, and Discontinuation of Therapy

Prescribe TUSSIONEX Pennkinetic for the shortest duration that is consistent with individual patient treatment goals [see Warnings and Precautions (5.1)].

Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy [see Warnings and Precautions (5.2)].

Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [see Warnings and Precautions (5.4)]. If a patient requires a refill, reevaluate the cause of the cough and assess the need for continued treatment with TUSSIONEX Pennkinetic, the relative incidence of adverse reactions, and the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1)].

Do not abruptly discontinue TUSSIONEX Pennkinetic in a physically-dependent patient [see Drug Abuse and Dependence (9.3)]. When a patient who has been taking TUSSIONEX Pennkinetic regularly and may be physically dependent no longer requires therapy with TUSSIONEX Pennkinetic, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.